Maccura Biotechnology Price To Book vs. EBITDA

300463 Stock   14.00  0.23  1.62%   
Based on the key profitability measurements obtained from Maccura Biotechnology's financial statements, Maccura Biotechnology Co may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Maccura Biotechnology's ability to earn profits and add value for shareholders.
For Maccura Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Maccura Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Maccura Biotechnology Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Maccura Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Maccura Biotechnology Co over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Maccura Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Maccura Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maccura Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Maccura Biotechnology EBITDA vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Maccura Biotechnology's current stock value. Our valuation model uses many indicators to compare Maccura Biotechnology value to that of its competitors to determine the firm's financial worth.
Maccura Biotechnology Co is number one stock in price to book category among its peers. It also is number one stock in ebitda category among its peers totaling about  459,912,561  of EBITDA per Price To Book. At present, Maccura Biotechnology's EBITDA is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all model that can be used if you cannot value Maccura Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Maccura Biotechnology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Maccura EBITDA vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Maccura Biotechnology

P/B

 = 

MV Per Share

BV Per Share

 = 
1.33 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Maccura Biotechnology

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
613.34 M
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Maccura EBITDA Comparison

Maccura Biotechnology is currently under evaluation in ebitda category among its peers.

Maccura Biotechnology Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Maccura Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Maccura Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Maccura Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Maccura Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income451.5 M651 M
Income Before Tax305.4 M593.2 M
Net Income Applicable To Common Shares814.1 M494.3 M
Net Income312.6 M481.8 M
Income Tax Expense100.8 M102.7 M
Net Income From Continuing Ops304.7 M594.8 M
Total Other Income Expense Net-2.4 M-2.5 M
Net Interest Income-24.4 M-25.6 M
Interest Income10 M5.5 M
Change To Netincome128.1 M107.9 M

Maccura Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Maccura Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Maccura Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Maccura Biotechnology's important profitability drivers and their relationship over time.

Use Maccura Biotechnology in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Maccura Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Maccura Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Maccura Biotechnology Pair Trading

Maccura Biotechnology Co Pair Trading Analysis

The ability to find closely correlated positions to Maccura Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Maccura Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Maccura Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Maccura Biotechnology Co to buy it.
The correlation of Maccura Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Maccura Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Maccura Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Maccura Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Maccura Biotechnology position

In addition to having Maccura Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Industrials ETFs Thematic Idea Now

Industrials ETFs
Industrials ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Industrials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Industrials ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Maccura Stock

To fully project Maccura Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Maccura Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Maccura Biotechnology's income statement, its balance sheet, and the statement of cash flows.
Potential Maccura Biotechnology investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Maccura Biotechnology investors may work on each financial statement separately, they are all related. The changes in Maccura Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Maccura Biotechnology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.